Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders


Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis.


Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.globalbloodtx.com

Recent News

March 13, 2017
Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results

March 1, 2017
Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March

February 27, 2017
Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

Read More News

Associated Team Members

Kevin Starr
Partner

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner

Glenn Pierce, M.D., Ph.D.
ENTREPRENUER-IN-RESIDENCE